Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trial
Official title:
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) who have completed study 161403 will be able to take part in this study. The main aim of the study is to evaluate side effects in the long-term treatment with HYQVIA/HyQvia. All participants will receive HYQVIA/HyQvia in the same way as they were receiving in study 161403. The dosing interval of HYQVIA/HyQvia can be adjusted after 12 weeks of treatment in study 161505 if the study doctor determines that it is safe to do so. Participants will visit the clinic within 1 week after the first and second dose of HYQVIA/HyQvia and then every 12 weeks for the duration of the study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04356781 -
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
|
||
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Terminated |
NCT01225276 -
Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP
|
Phase 2/Phase 3 | |
| Completed |
NCT02892890 -
Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
|
N/A | |
| Active, not recruiting |
NCT03584022 -
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
|
N/A | |
| Terminated |
NCT02317562 -
Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302
|
Phase 3 | |
| Recruiting |
NCT06325878 -
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
N/A | |
| Recruiting |
NCT06290128 -
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
|
Phase 3 | |
| Completed |
NCT02293460 -
Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
|
Phase 3 | |
| Completed |
NCT02017769 -
MRI in Diagnosing and Monitoring CIDP
|
N/A | |
| Withdrawn |
NCT05257733 -
Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases (CIDP Echo-nerf)
|
||
| Completed |
NCT03967899 -
Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
||
| Not yet recruiting |
NCT04978623 -
Role of High Frequency Ultrasound in Demyelinating Polyneuropathies
|
||
| Active, not recruiting |
NCT02404298 -
Transcriptome Analysis of the Peripheral Blood in CIDP
|
N/A | |
| Completed |
NCT00099489 -
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|
Phase 2 | |
| Completed |
NCT01625182 -
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
|
Phase 3 | |
| Completed |
NCT02549170 -
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|
Phase 3 | |
| Active, not recruiting |
NCT04658472 -
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 2 | |
| Withdrawn |
NCT04529291 -
InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
N/A |